The main obstacle to better antimicrobial resistance (AMR) management is not a technological deficit. Advanced diagnostics exist, but healthcare systems struggle to implement them. The key is generating real-world evidence and health economic data to convince policymakers and change clinical practice.

The ambitious goal of prescribing no antibiotics without a diagnostic by 2030 cannot be achieved by technology alone. It requires a systemic effort involving national action plans and policy reinforcement, driven by partnerships between public entities, private companies, academics, policymakers, and scientists.

Beyond climate impact, 70% of antibiotics are fed to farm animals, fostering superbugs that threaten modern medicine. Industrial farms also act as incubators for zoonotic diseases, posing catastrophic risks to global health and the economy.

Counter to the popular focus on wild animal markets, a UN-backed report by leading zoonotic disease specialists listed increased meat consumption and industrial animal farming as the top two of seven likely causes for the next global pandemic, as every additional animal is a potential vector.

Evolutionary modeling shows that taking antibiotics beyond symptom resolution can be counterproductive. It needlessly kills off susceptible bacteria, creating a perfect environment for resistant strains to flourish. The optimal strategy is often to stop once the immune system can handle the rest, contrary to decades of medical advice.

Investors are hesitant to fund antimicrobial resistance research because the field has been stuck for decades trying the same approaches—traditional antibiotics and vaccines—and expecting different results. A fundamental shift in scientific strategy is required to regain investor confidence and make progress against superbugs.

MIT Professor Jim Collins estimates a $20 billion investment could fund the R&D and clinical trials for 15-20 new antibiotics, solving the crisis for decades. This cost is a fraction of recent tech investments, framing an existential threat as a solvable, relatively affordable problem.

Effective new antibiotics are used sparingly to prevent resistance, which makes them commercially unviable for pharma companies. This "vicious circle" of low usage leading to low revenue actively disincentivizes the development of the very drugs needed to combat superbugs.

Even when AMR experts explain that the crisis could be deadlier than cancer, their own families dismiss it as an overreaction. This personal anecdote highlights the severe public awareness gap surrounding one of the world's most urgent health crises, even among those closest to the issue.